Futura Medical PLC
LSE:FUM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Futura Medical PLC
Operating Income
Futura Medical PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Futura Medical PLC
LSE:FUM
|
Operating Income
-£2.2m
|
CAGR 3-Years
31%
|
CAGR 5-Years
21%
|
CAGR 10-Years
8%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£9.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$14B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
10%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$742m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Operating Income
-£33.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Operating Income
£33.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
Futura Medical PLC
Glance View
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
See Also
What is Futura Medical PLC's Operating Income?
Operating Income
-2.2m
GBP
Based on the financial report for Jun 30, 2025, Futura Medical PLC's Operating Income amounts to -2.2m GBP.
What is Futura Medical PLC's Operating Income growth rate?
Operating Income CAGR 10Y
8%
Over the last year, the Operating Income growth was 46%. The average annual Operating Income growth rates for Futura Medical PLC have been 31% over the past three years , 21% over the past five years , and 8% over the past ten years .
